Melanotan II
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Best understood as a tanning compound first and a libido/appetite compound second.
Skin surveillance is the gate: baseline mole photos, melanoma/atypical-nevus history, photosensitizer review, and conservative UV exposure matter more than endocrine monitoring.
Best understood as a tanning compound first and a libido/appetite compound second. The practical target is building a darker melanin base with planned UV exposure; libido enhancement is common enough to matter, but PT-141 or other options are cleaner when sexual function is the main goal.
The real tax is not endocrine suppression; it is acute melanocortin side effects plus skin surveillance. Nausea and flushing are common early, mole darkening is expected and needs baseline photos, and melanoma-history or atypical-nevus users should treat MT-2 as a dermatologist-supervised or avoid lane.
For very fair users who burn instead of tan, MT-2 can change the whole summer equation: reported 2-6 week loading patterns plus progressive UV exposure can produce a deep tan that may persist 6-9 months after stopping. The tradeoff is that dermatology discipline, product-identity confidence, and UV pacing become part of the risk profile.
High for tanning when the user combines a tolerated dose with consistent UV exposure and adequate time. Community consensus is bullish but bounded: MT-2 works unusually well for fair-skin tanning, yet nausea, mole changes, and poor UV planning are the common reasons people stop or get into trouble.
Intro
Melanotan II (MT-2) is a synthetic cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH), developed at the University of Arizona in the early 1990s by Dorr, Hruby, and Hadley as a potential sunless tanning agent and skin cancer chemopreventive. Its full chemical name is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. The cyclic structure and D-Phe substitution confer resistance to enzymatic degradation and dramatically increased receptor binding affinity compared to native alpha-MSH — hence its 'superpotent' melanotropic activity in vitro.
Unlike native alpha-MSH, which is primarily MC1R-selective, MT-2 binds non-selectively to all five melanocortin receptors (MC1R through MC5R). This explains its broad pharmacological profile: MC1R drives melanogenesis in melanocytes; MC3R and MC4R mediate libido, appetite suppression, and sexual behavior in the central nervous system; MC2R is the ACTH receptor (with minor adrenocortical effects); MC5R influences exocrine glands.
MT-2 was never commercialized for tanning, but its libido-enhancing effects via MC4R redirected it toward sexual dysfunction research. A closely related compound, PT-141 (bremelanotide), was subsequently developed with MC3R/MC4R selectivity (excluding MC2R) and reached FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder. MT-2 has no regulatory approval for any indication but has been used in gray-market communities since the early 2000s.
Community use began in bodybuilding communities and has expanded substantially, with particularly strong adoption in the UK. The compound is WADA-compliant as of 2025 — not listed on the Prohibited List — making it accessible to competitive athletes. It has no effect on the HPTA axis, requires no post-cycle therapy, and can be stopped at any time without a taper.
Observed Effects
The dominant effect is accelerated melanin production and skin tanning. MT-2 activates MC1R in melanocytes, driving the cAMP-tyrosinase cascade that synthesizes eumelanin — the brown/black photoprotective form of melanin.
UV exposure is required to 'develop' this melanin into visible pigment; without UV, MT-2 alone produces only a slight yellow tinge from basal melanin increase.
For fair-skinned users (Fitzpatrick I–II), the transformation is consistently described as remarkable. Multiple first-person logs document going from 'always burns, never tans' to a deep, lasting tan within 3–6 weeks of loading combined with regular UV exposure. The tan persists approximately 6–9 months after stopping even without maintenance dosing — a pharmacoeconomic advantage that makes one loading cycle per spring sufficient for year-round color.
Visible timeline: Week 1 — subtle skin priming, minimal visible change. Week 2–3 — noticeable tan with consistent UV exposure. Week 4+ — full established tan. Fitzpatrick III–IV users see results in 7–14 days; Fitzpatrick I users may need 4–6 weeks and 4–5 vials (40–50 mg cumulative).
The biological tanning effect window extends approximately 33–36 hours after a dose, despite a plasma half-life of only 1–2 hours. This discrepancy is explained by the downstream cascade: MT-2 binds MC1R → activates cAMP → triggers tyrosinase activation → melanin synthesis continues in melanocytes for hours after the peptide clears plasma. This means bedtime dosing productively primes melanocytes for next-day UV exposure.
Libido enhancement is the most consistent secondary effect, mediated by MC3R/MC4R agonism in the hypothalamus. In the Wessells 1998 Phase II clinical trial, 17 of 20 men with organic erectile dysfunction achieved penile erections at 0.025 mg/kg MT-2. Community users reliably describe increased sexual desire and spontaneous erections, typically onset within 1–4 hours of injection. However, experienced community members consistently rate this libido effect as secondary to tanning and note that PT-141 and semax produce stronger, more targeted libido effects when that is the primary goal.
Additional reported effects include moderate appetite suppression (MC4R hypothalamic pathway), improved mood and neurotypical effects (dopaminergic modulation via MC4R/MC3R), and universal mole darkening (due to high MC1R density in moles — 10–100× surrounding skin).
Field Reports
The defining community experience is the tanning transformation. Fair-skinned users who have never successfully tanned consistently document going from 'always burns, never tans' to deep, lasting color within a few weeks.
One PLE sufferer described achieving a visible tan 'for the first time in my life' after approximately one month — having lived in California and Hawaii for years without being able to spend time in the sun. Multiple UK community logs from 2006 onward document similar results in pale-skinned British users for whom tanning bed sessions before MT-2 produced nothing.
The side effect experience is the most variable dimension. Some users report severe nausea and flushing even at 50 mcg — described as 'queasy and wheezy, bright purple and swollen for about 20 minutes.' Others run 1–1.5 mg/day with minimal side effects after the first few doses. One low-dose self-experimentation case described 100 mcg at night as the threshold where side effects were hardly noticeable while sun tolerance improved dramatically.
Mole darkening is a near-universal experience in extended users. Multiple community members document all existing facial moles darkening noticeably during loading. The community response is consistent: this is expected, photograph baseline, monitor for changes, consult a dermatologist if anything new or changing appears. The more alarming case — a new mole appearing after a single dose — was met with the same recommendation: dermatologist evaluation before continuing.
Protocol iteration across cycles is common. First runs often have suboptimal results due to product-quality issues, incorrect dose, or insufficient UV scheduling. Second and subsequent runs with refined protocols consistently produce better results. The most commonly refined variables are: product consistency, starting dose, UV schedule timing relative to dosing, and side effect management strategy.
The Australian high-dose case documents what happens at the extreme end: 500–2500 mcg/day over 65 days (7 vials), beard color darkening from ginger to dark brown, 30 new freckles (most subsided), and at the highest doses (2500 mcg), painful erections lasting up to 6 hours on the first days. This data point is useful context for understanding dose-response — none of these extreme effects are reported at standard community loading doses of 500 mcg/day.
Community Consensus
The experienced community frames MT-2 as a tanning compound where libido enhancement is a notable secondary benefit, not as a primary libido drug.
The practical hierarchy is clear: users who want tanning with libido as a bonus choose MT-2, while users chasing sexual function alone usually separate that goal and pick a more targeted melanocortin option.
The compound's non-hormonal, WADA-compliant, no-PCT profile drives adoption outside traditional anabolic circles. It is often treated as a gateway peptide because it does not affect the HPTA axis, natural testosterone production, or require a recovery protocol. That beginner-friendly reputation is only half true: the endocrine tax is low, but the dermatology and UV-planning tax is real.
The polymorphous light eruption (PLE / sun poisoning) use case is an important application beyond cosmetics. PLE sufferers who cannot tolerate UV exposure use MT-2 to build a protective melanin base before sun season. For these users, the reported benefit is not just looking darker; it can mean being able to spend time outdoors without triggering the same light reaction.
Product quality is a critical practical variable. Community members consistently report order-of-magnitude differences in potency across batches. The same labeled dose that produces full effects from one batch may produce barely perceptible effects from another, so starting low with any new batch and retitrating is standard practice.
The melanoma concern is actively debated. The practical consensus is neither panic nor dismissal: UV exposure remains the carcinogenic driver, more eumelanin may reduce per-photon UV damage, but MT-2 also darkens moles and could theoretically complicate surveillance in genetically or dermatologically predisposed users. The workable position is baseline photos, conservative UV exposure, hard stop-and-check thresholds for changing lesions, and avoidance in melanoma-history or atypical-nevus contexts.
Risks & Monitoring
Side effects are dose-dependent and concentrated in the first hours after each injection. The most common are facial flushing (near-universal at ≥250 mcg in first-time users) and nausea (common at ≥250 mcg without countermeasures).
Both are acute — flushing resolves in 20–60 minutes; nausea typically 1–3 hours. Community members consistently describe the adverse effect window as the primary barrier to use, and the primary reason bedtime dosing became standard.
Effective countermeasures exist: diphenhydramine (Benadryl) 30–45 minutes before injection significantly reduces facial flushing. Ondansetron (Zofran, a 5-HT3 antagonist used for chemotherapy nausea) can completely eliminate nausea when used as a premedication — this combination allows users to dose at convenient times rather than being forced to dose only at night. Dose reduction also reliably reduces side effect burden.
Fatigue and somnolence occur in some users, particularly early in the loading phase. Severity varies from mild to significant — one community case documented sleeping the majority of a day during early loading. Grade II somnolence was noted in the Phase I clinical trial at 0.03 mg/kg. Bedtime dosing converts this from a problem into an advantage.
Mole darkening is near-universal in extended users. This is an expected pharmacological effect: moles have 10–100× higher MC1R density than surrounding skin, causing them to respond to systemically administered MT-2 before the surrounding skin visibly tans. Darkening of existing moles in isolation is not a safety signal — it is a predictable receptor effect. However, any mole that is new, enlarging, changing shape, developing irregular borders, becoming multi-colored, or bleeding warrants dermatologist evaluation before continuing. Community reports include a case of a user who developed a new red mole on their hand after a single small dose; the community consensus recommendation was dermatologist evaluation regardless of the dose that precipitated it.
White spots developing during MT-2 use are almost always tinea versicolor (Malassezia furfur overgrowth), not a drug effect. UV tanning darkens surrounding skin while fungus-affected patches remain pale, creating high-contrast white spots. This is not caused by MT-2. Treatment: ketoconazole topical; fluconazole or itraconazole orally for severe cases.
At extreme overdose (10 mg injections — approximately 10–20× the typical community dose), case reports document erectile dysfunction, elevated blood pressure, elevated hematocrit, and nephrotoxicity (PMID 31953620). These effects are not applicable to community-standard dosing of 0.1–1.5 mg. Experienced community moderators explicitly confirm no blood pressure changes across multiple cycles at standard doses.
The melanoma concern merits honest discussion: the clinical literature contains case reports associating MT-2 use with melanoma. The mechanistic concern is that MC1R stimulation could theoretically promote malignant transformation in pre-existing atypical melanocytes. The counterargument — supported by in vitro data — is that increased eumelanin confers photoprotection, reducing per-photon UV-induced DNA damage. Current evidence cannot confirm MT-2 as a direct carcinogen at community doses. Practical position: do not use if you have a history of melanoma, dysplastic nevi syndrome, or multiple atypical moles; monitor all moles with baseline photographs.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
The article flags this as the single most important pre-MT-2 step. Moles have 10-100x higher MC1R density than surrounding skin and darken predictably during loading — without baseline photographs, distinguishing expected pharmacological darkening from genuinely concerning change becomes impossible. The article explicitly states 'photograph all moles at baseline before starting' and lists the action thresholds (new mole, growth, shape change, irregular borders, multi-color, bleeding) that warrant dermatologist evaluation.
The article designates melanoma history, dysplastic nevi syndrome, and multiple atypical moles as a hard contraindication. A pre-MT-2 dermatologist visit confirms the user is not in this category — MC1R stimulation in melanocytes with pre-existing oncogenic mutations could theoretically promote malignant proliferation per the article's mechanism discussion.
Standard pre-injection screening. The article notes BP changes are NOT seen at community-standard doses (0.1-1.5 mg), but extreme overdose case reports (10 mg, 10-20x typical) document elevated BP. Baseline establishes the user's normal range before any MC2R/MC3R/MC4R-mediated transient effects could occur.
Standard pre-injection screening. The article notes the extreme overdose case reports also documented elevated hematocrit and nephrotoxicity — not relevant at standard doses but baseline CBC + comprehensive metabolic panel rules out unrelated issues that could be misattributed if AEs emerge.
The article positions libido as a secondary effect and recommends PT-141 or semax when libido is the primary goal. For users adding MT-2 with libido as a co-goal, baseline T and E2 contextualize whether expected libido enhancement is hormonal-foundation-dependent. Skip if tanning is the only goal.
The article lists the photosensitizing drug interaction as 'hard' severity in stackingConflicts: tetracyclines, quinolones, sulfonamides, amiodarone, St. John's Wort, thiazide diuretics, topical retinoids. MT-2 primes melanocytes; photosensitizers amplify per-photon UV damage. The combination at UV exposures that would otherwise be safe can produce phototoxic burns. A medication review before UV exposure begins is non-negotiable per the article's framing.
The article specifies '2 weeks and 4 weeks into loading' for mole re-photography. Week 2 catches the earliest darkening that occurs disproportionately at moles before surrounding skin tans — establishes the user's individual response pattern and triggers dermatologist consult if any non-darkening change (new mole, shape, border) is visible.
The article's second specified re-photography point. By week 4 most users have completed loading or are deep into it. Comparing week 4 photos against baseline catches changes that developed after the initial darkening response and informs whether to continue, reduce, or stop. The article documents one community case of a new red mole appearing after a single small dose — week 4 surveillance catches this class of finding.
The article notes individual variation is high — some users tolerate 1.5 mg/day comfortably while others have severe AEs at 50 mcg. A simple log (dose, time of day, nausea severity, flushing duration, sleep quality) during loading identifies the user's personal sweet spot and informs antihistamine/Zofran premedication needs. Documented low-dose self-experimentation emerged from this kind of iterative tracking.
The article explicitly addresses the white-spot question: white spots developing during MT-2 use are almost always tinea versicolor (Malassezia furfur), not a drug effect — UV tans surrounding skin while fungus-affected patches remain pale. The article lists ketoconazole topical or fluconazole/itraconazole oral as treatment. Only triggered if white spots appear; not a routine check.
The article frames mole monitoring as the correct safety response to the melanoma concern, not compound avoidance. After loading + maintenance phases, ongoing annual full-body skin examinations with comparison against the baseline photo archive is the article's recommended posture. The compound's pharmacological effect on mole darkening persists beyond active dosing — surveillance does too.
The article's hard rule: any mole that is new, enlarging, changing shape, developing irregular borders, becoming multi-colored, or bleeding warrants dermatologist evaluation before continuing MT-2. This is not optional — it's the explicit action threshold the article repeats in both adverseEffects and practicalConsiderations.
Avoid With
Do not combine Melanotan II with the following. Sorted highest-severity first.
Why:MT-2 primes melanocytes and increases UV skin sensitivity; photosensitizing drugs independently increase UV damage per photon. The combination can amplify UV burns and phototoxic reactions at UV exposures that would otherwise be safe.
What to do:Check all current medications for photosensitivity before starting UV exposure on MT-2. Phototoxic drug interactions are dose-dependent and predictable. This is not a theoretical concern.
Why:MC1R stimulation in melanocytes with pre-existing oncogenic mutations could theoretically promote malignant proliferation. The anti-melanoma in vitro data applies to normal melanocytes; the risk-benefit calculation is unfavorable in the context of pre-existing melanocyte dysplasia.
What to do:Relative contraindication based on mechanism. Conservative clinical position is to avoid entirely in these populations.
Why:Additive MC3R/MC4R activation increases cumulative side effect burden (nausea, priapism risk, potential blood pressure effects). Individual doses of each are well-tolerated; stacking amplifies the adverse effect profile.
What to do:Low-dose stacking for specific protocols is used by advanced community members. The concern is with full-dose concurrent administration of both compounds on the same day.
Why:Both compounds produce erections via complementary pathways (MT-2 via central MC4R; PDE5i via peripheral nitric oxide/cGMP). Combined use at high doses of each can produce prolonged or painful erections. Low-dose tadalafil for cardiovascular benefit with standard MT-2 loading is generally tolerated.
What to do:Risk is most relevant when stacking with intent to maximize erectile effect. Standard 500 mcg MT-2 + standard tadalafil (5 mg daily) is a common and generally well-tolerated combination.
Protocols By Goal
Fair-skin tanning reports describe low initial exposure, gradual escalation only if tolerated, delayed UV exposure after the first few days, and stopping or reducing dose when nausea, flushing, fatigue, or mole changes become prominent. Rapid pre-trip tanning reports use more aggressive daily loading plus frequent UV exposure; that pattern raises burn and dermatology risk and should not be framed as a safe shortcut.
Year-round maintenance reports usually involve much lower frequency once a tan is established. PLE-oriented reports describe starting weeks before sun season so a melanin base is present before major exposure; this remains self-report, not validated disease treatment. Libido effects often appear within hours of dosing, but if libido is the primary goal, more targeted melanocortin options are usually discussed instead.
Dosing Details
Reported MT-2 use clusters around conservative sensitivity tests, gradual loading, and lower-frequency maintenance after color is established.
Community dose tiers often describe 100-250 mcg as conservative, 500 mcg/day as a common loading reference, and 1000+ mcg/day as a high-side pattern with more nausea, flushing, and mole-darkening concern. Nasal products are discussed as less predictable than injectable use and vary widely in delivered amount. This is observed practice, not a recommendation.
Loading reports usually describe daily exposure for 2-4 weeks, longer for very fair Fitzpatrick I users, with progressive UV only after several days of melanocyte priming. The safer pattern described by experienced users is short, incremental UV exposure rather than aggressive sunbed or sun exposure. Maintenance reports range from weekly to occasional use, and many users describe one seasonal loading period with color persisting for months.
Libido-focused one-off use is a secondary pattern, but PT-141 is more purpose-built for that lane. MT-2 should be framed as a tanning-risk compound with melanocortin side effects, not as a casual sexual-function tool.
Stacks & Alternatives
Pre-sex libido boost without requiring MT-2's full-dose nausea cycle. PT-141 is MC3R/MC4R selective (excludes MC2R) and purpose-built for sexual function. Use MT-2 for daily tanning protocol; use PT-141 separately for sexual function if needed. Most community members choose one or the other based on primary goal rather than running both simultaneously.
MC1R-selective tanning without MC3R/MC4R sexual side effects. Some users combine low-dose MT-1 + MT-2 for enhanced tanning with a reduced libido/nausea profile. One documented men's-health forum case: MT-1 + MT-2 (250 mcg each) with 30 min daily sun produced an 'extremely dark to the point of extreme' tan — user stopped because it was too dramatic.
Carotenoids provide additional skin color (orange/yellow pigment layer) that synergizes cosmetically with melanin-based tanning. One documented community protocol combines MT-2 nasal spray with this oral + topical carotenoid stack for comprehensive skin color optimization.
Alternatives
Stack Cost
Moderate stack tax: MT-2 is non-suppressive and cheap, but it consumes a real dermatology/UV-risk lane and adds melanocortin side effects, photosensitizer checks, and product-potency uncertainty.
The article makes mole mapping, baseline photography, week-2/week-4 rechecks, and dermatologist escalation central to use because MC1R activation darkens moles and can complicate melanoma surveillance.
The hard interaction lane is photosensitizing drugs plus UV exposure. MT-2 primes melanocytes while tetracyclines, quinolones, sulfonamides, amiodarone, St. John's Wort, thiazides, and topical retinoids can amplify phototoxic burn risk.
Non-selective MC3R/MC4R activation drives nausea, flushing, yawning, fatigue, libido, appetite suppression, and possible blood-pressure effects. The burden is acute and dose-dependent, but it shapes timing and tolerability.
The common route is subcutaneous injection or nasal spray, with simple reconstitution and no taper. The logistical tax is lower than hormonal injectables but still requires sterile handling and careful unit conversion.
The article notes major potency variability across unapproved products. The compound can be inexpensive per tan, but product changes require renewed caution and identity/potency confidence.
- ·Do not start without baseline mole photographs and a plan for dermatologist review if any lesion is new, changing, bleeding, irregular, or multi-colored.
- ·Avoid entirely with melanoma history, dysplastic nevi syndrome, or multiple atypical moles unless a dermatologist is directly supervising.
- ·Check all medications and topicals for photosensitivity before adding UV exposure.
- ·Do not front-load high doses before major UV exposure; establish melanin gradually and increase UV exposure progressively.
- ·Treat libido stacks separately: avoid full-dose same-day MT-2 plus PT-141 or high-dose PDE5 inhibitor escalation unless the user is experienced and accepts priapism/nausea risk.
- ·Baseline full-body skin exam, mole photographs, and repeat mole checks during loading.
- ·Medication review for photosensitizers before UV exposure.
- ·Dose/timing log for nausea, flushing, fatigue, libido, blood pressure, and appetite effects.
- ·Antinausea and antihistamine planning for users who cannot tolerate the acute side-effect window.
- ·Progressive UV schedule rather than aggressive sunbed or sun exposure while loading.
The article calls MT-2 a gateway peptide because it is non-hormonal and requires no PCT, but it is not casual: correct use depends on skin-risk screening, mole surveillance, photosensitizer review, conservative titration, and UV discipline.
- ·History of melanoma, dysplastic nevi syndrome, or multiple atypical moles.
- ·Current photosensitizing medications or topical retinoids plus planned UV exposure.
- ·Plan includes high-dose front-loading before vacation or sunbed exposure.
- ·The user wants libido effects primarily and is stacking PT-141 or high-dose PDE5 inhibitors.
There is no suppression, taper, or withdrawal protocol. Stopping ends new melanocortin exposure, but the tan and mole darkening can persist for months, so dermatology surveillance continues after discontinuation.
- ·Persistent tan or mole darkening for months after stopping.
- ·Needing dermatology review for any lesion change that appeared during or after loading.
- ·Loss of maintenance color over time if UV exposure and maintenance dosing stop.
Photograph all moles before dosing and repeat during loading. Stop and get dermatology review for new, evolving, irregular, multi-color, bleeding, or enlarging lesions.
Review medications and topicals before UV. Delay MT-2/UV exposure or use strict UV avoidance when a photosensitizer is active.
Return to the lowest tolerated dose, dose at bedtime, titrate slowly, and use symptom logs. Antiemetic or antihistamine support should not be used to justify reckless dose escalation.
Use MT-2 for tanning and choose PT-141 separately when libido is the main goal. Reduce overlapping melanocortin/PDE5 burden and seek care for prolonged painful erections.
The article treats this as the core dermatology contraindication because MC1R stimulation changes melanocyte activity and complicates lesion surveillance.
These are the article's explicit stop-and-evaluate thresholds during MT-2 use.
MT-2 plus photosensitizers can amplify UV injury at exposures that would otherwise be tolerated.
The evidence review and article both connect melanocortin activity with transient blood-pressure effects, libido/erection effects, and rare serious overdose reports.
Practical Setup
Operational details matter because MT-2 is an unapproved injectable peptide and potency varies across products.
Public guidance should avoid step-by-step reconstitution or injection instructions; the reader-facing takeaway is that inaccurate concentration, poor handling, and product switching can make the same nominal dose feel very different.
Mole monitoring is the central safety practice described in experienced reports: baseline photographs, repeat comparison during loading, and dermatology review for any mole that is new, growing, changing shape, developing irregular borders, becoming multi-colored, or bleeding. Darkening of existing moles can be pharmacologically expected, but that does not replace clinical evaluation when morphology changes.
Side-effect mitigation in reports centers on lower exposure, bedtime timing, and stopping when nausea, flushing, blood-pressure symptoms, or lesion changes become concerning. UV exposure should be progressive. High-dose use immediately before major UV exposure can create severe burn risk, especially without an established tan base. Photosensitizing medications add another reason to avoid casual UV escalation.
Mechanism Deep Dive
MT-2 is a cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2; MW 1024.18 g/mol) developed as a superpotent analog of alpha-MSH.
The D-Phe substitution at position 7 and cyclic backbone confer resistance to enzymatic degradation and dramatically increased receptor binding affinity compared to native alpha-MSH.
Receptor profile: non-selective agonist at all five melanocortin receptors (MC1R–MC5R). Key mechanistic distinction from PT-141: PT-141 selectively agonizes MC3R and MC4R, excluding MC2R (the ACTH receptor) — MT-2 activates MC2R as well, conferring minor adrenocortical effects absent with PT-141.
Melanogenesis (MC1R pathway): MC1R activation in melanocytes → increased intracellular cAMP → protein kinase A activation → phosphorylation of CREB transcription factor → upregulation of MITF (master melanocyte transcription factor) → increased tyrosinase expression → enzymatic conversion of tyrosine to eumelanin (brown/black photoprotective melanin). UV normally triggers this cascade via keratinocyte release of alpha-MSH; MT-2 bypasses the UV trigger and drives the cascade systemically and continuously. Moles have 10–100× higher MC1R density than surrounding skin — they respond to systemically administered MT-2 even without UV, explaining the characteristic early and disproportionate mole darkening.
Erectile function (MC4R pathway): MC4R agonism in the paraventricular nucleus of the hypothalamus and sacral spinal cord activates pro-erectile central circuits. This mechanism is complementary to and independent of the PDE5 pathway targeted by sildenafil/tadalafil. The Wessells 1998 Phase II clinical trial demonstrated this clinically: 17 of 20 men with organic erectile dysfunction unresponsive to conventional treatment achieved penile erections at 0.025 mg/kg MT-2. MC3R agonism also contributes to libido via mesolimbic dopaminergic modulation.
Appetite suppression (MC4R hypothalamic pathway): MC4R neurons in the arcuate nucleus modulate energy homeostasis. Leptin and melanocortin signaling are tightly coupled; MC4R agonism suppresses appetite drive.
Pharmacokinetics: subcutaneous bioavailability approximately 100%. Plasma half-life approximately 1–2 hours. Biological tanning effect window approximately 33–36 hours — significantly longer than the plasma half-life because the downstream melanocyte cAMP/tyrosinase activation cascade persists long after the parent peptide has cleared from plasma. This explains why once-daily dosing is effective and why bedtime dosing productively primes next-day sun exposure.
Photoprotection mechanism: eumelanin absorbs UV photons and dissipates energy as heat, physically shielding the DNA of basal keratinocytes from UV-induced pyrimidine dimer formation. More eumelanin = lower per-photon mutagenic DNA damage at a given UV dose. In vitro data (PMID 31968661, 7983590, 28703311, 8637402) demonstrates melanocortin receptor activation in normal melanocytes suppresses pro-oncogenic pathways including PTEN-driven melanocyte stress and COX-2-mediated inflammation — supporting the original University of Arizona hypothesis that MT-2-driven melanin production is genuinely chemopreventive against UV-induced skin cancer.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
MT-2 produced tanning activity in humans after five low-dose subcutaneous administrations and the recommended single dose for future Phase I studies was 0.025 mg/kg/day.
Very small male-only pilot. Supports biological tanning activity and acute tolerability signals, not broad safety or modern community loading protocols.
In men with erectile dysfunction, 17 of 20 achieved penile erections after MT-2 and increased sexual desire occurred after 13/19 MT-2 doses versus 4/21 placebo doses.
Male ED population; useful for libido/erection mechanism and nausea/yawning side effects, not evidence for tanning protocols in healthy users or women.
Fair-skinned community users commonly report visible tanning within 3-6 weeks of loading and tan persistence for 6-9 months after stopping.
High practical relevance but not controlled. Outcomes depend on Fitzpatrick type, UV schedule, product potency, and adherence.
At extreme overdose around 10 mg, case reports document systemic toxicity signals including blood pressure elevation, elevated hematocrit, nephrotoxicity, or rhabdomyolysis-type injury.
These reports do not represent standard 0.1-1.5 mg community dosing, but they justify conservative dose ceilings and baseline BP/CBC/CMP context.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.